Press Releases

Press Releasesadmin2023-06-07T15:58:22-04:00

Most recent news

August 13, 2024

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

August 8, 2024

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
July 24, 2024

Virpax Regains Compliance with Nasdaq Minimum Bid Price
July 10, 2024

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
July 8, 2024

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
May 29, 2024

Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
May 15, 2024

Virpax Announces Pricing of $2.25 Million Public Offering
May 13, 2024

Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
April 30, 2024

Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
March 26, 2024

Virpax Pharmaceuticals Reports 2023 Year-End Results
February 27, 2024

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
February 27, 2024

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 7, 2024

Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
December 29, 2023

Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
November 17, 2023

Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing

BUSINESS INQUIRIES

Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
610.727.4597
‍info@virpaxpharma.com

INVESTOR INQUIRIES

Betsy Brod
Affinity Growth Advisors
‍betsy.brod@affinitygrowth.com

MEDIA INQUIRIES

Public Relations
Virpax Pharmaceuticals, Inc.
‍pr@virpaxpharma.com

Nasdaq_Logo_wht

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

Nasdaq_Logo_wht

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

© Virpax^® Pharmaceuticals. All Rights Reserved.

© Virpax^® Pharmaceuticals. All Rights Reserved.

Follow @VirpaxPharma

Follow @VirpaxPharma